Analyst consensus rating
Edwards Lifesciences Analyst Rating: Buy
EW is rated Buy by 26 analysts with a $100.96 target. As of 2026-08-23.
Direct answer
Edwards Lifesciences's consensus rating is Buy.
26 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $100.96.
Forecast evidence checked August 23, 2026.
Get free Edwards Lifesciences email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $89.79
- Average price target
- $100.96
- High price target
- $110.00
- Low price target
- $84.00
- Low target gap
- -6.4%
- Target upside
- +12.4%
- High target gap
- +22.5%
- Target range width
- 29%
- Consensus rating
- Buy
- Analysts
- 26
- Evidence date
- August 23, 2026
- Valid through
- August 30, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Edwards Lifesciences?
Edwards Lifesciences has a verified Buy consensus. The same dataset has an average price target of $100.96.
How far are Edwards Lifesciences's low and high targets from the recorded price?
The low target implies -6.4%, while the high target implies +22.5%.
How many analysts are included in Edwards Lifesciences's consensus?
The verified consensus includes 26 analysts.
How is Edwards Lifesciences's target upside or downside calculated?
The average target of $100.96 is divided by the recorded price of $89.79, then one is subtracted to produce +12.4%. This does not guarantee a future return.
When was Edwards Lifesciences's analyst forecast verified?
The data was verified on 2026-08-23. The dataset is valid through 2026-08-30.